GSK aftermath: pharma grapples with compliance issues
This article was originally published in SRA
Executive Summary
GlaxoSmithKline's Chinese bribery scandal – which last month ended with the UK major being fined a record sum of nearly $490 million – has left the pharma industry pondering its next steps to meet a rising bar and the soaring costs of compliance1.